Limitations of the Research Despite promising animal studies, key limitations remain: Human studies are sparse: Most research is conducted in rodents with few clinical trials
Most improvement was achieved by BPC 157 regimens (42, 43) per-orally, parenterally and locally, even when complicated with relapse, poor healing of the fistulas, unhealed intestinal anastomosis (10, 11, 35, 42, 43) massive intestinal resection leading to short bowel (43) and functional incapability of the post-anastomotic remained intestine
Either way, both result in the same prohibition for athletes
Olympias compounded NAD+ may be administered via IV, IM, or SubQ routes, depending on your care plan
Thrombolytic Therapy
If the peptide restrictions are reversed through formal FDA rulemaking, compounding pharmacies would be legally allowed to prepare those peptides, but only as traditional, patient-specific compounded drugs, not as mass-market or FDA-approved therapies. If the peptides are formally added to the 503A bulk list, he says, pharmacies would have to follow the traditional 503A compounding rules
